Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer

DSpace/Manakin Repository

Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer

Citable link to this page

 

 
Title: Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer
Author: Ribi, K; Aldridge, J; Phillips, K-A; Thompson, A; Harvey, V; Thürlimann, B; Cardoso, F; Pagani, O; Coates, A S; Goldhirsch, A; Price, K N; Gelber, Richard David; Bernhard, J

Note: Order does not necessarily reflect citation order of authors.

Citation: Ribi, K, J Aldridge, K-A Phillips, A Thompson, V Harvey, B Thürlimann, F Cardoso, et al. 2012. Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer. British Journal of Cancer 106(10): 1618-1625.
Full Text & Related Files:
Abstract: Background: In the BIG 1-98 trial objective cognitive function improved in postmenopausal women 1 year after cessation of adjuvant endocrine therapy for breast cancer. This report evaluates changes in subjective cognitive function (SCF). Methods: One hundred postmenopausal women, randomised to receive 5 years of adjuvant tamoxifen, letrozole, or a sequence of the two, completed self-reported measures on SCF, psychological distress, fatigue, and quality of life during the fifth year of trial treatment (year 5) and 1 year after treatment completion (year 6). Changes between years 5 and 6 were evaluated using the Wilcoxon signed-rank test. Subjective cognitive function and its correlates were explored. Results: Subjective cognitive function and the other patient-reported outcomes did not change significantly after cessation of endocrine therapy with the exception of improvement for hot flushes (P=0.0005). No difference in changes was found between women taking tamoxifen or letrozole. Subjective cognitive function was the only psychosocial outcome with a substantial correlation between year 5 and 6 (Spearman's R=0.80). Correlations between SCF and the other patient-reported outcomes were generally low. Conclusion: Improved objective cognitive function but not SCF occur following cessation of adjuvant endocrine therapy in the BIG 1-98 trial. The substantial correlation of SCF scores over time may represent a stable attribute.
Published Version: doi:10.1038/bjc.2012.156
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3349183/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:11178965
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters